Join
Axogen Inc. logo

AXGN

NASDAQ

Axogen Inc.

SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
$43.36+0.54 (+1.26%)
News25/Ratings8

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Price$43.36-0.38 (-0.88%)
01:30 PM01:45 PM
News · 26 weeks44-93%
2025-12-14: 52025-12-21: 02025-12-28: 02026-01-04: 02026-01-11: 22026-01-18: 62026-01-25: 02026-02-01: 02026-02-08: 12026-02-15: 22026-02-22: 62026-03-01: 32026-03-08: 02026-03-15: 22026-03-22: 12026-03-29: 02026-04-05: 02026-04-12: 12026-04-19: 12026-04-26: 62026-05-03: 62026-05-10: 12026-05-17: 12026-05-24: 02026-05-31: 02026-06-07: 0
2025-12-142026-06-07
Mix1990d
  • Insider9(47%)
  • Other4(21%)
  • SEC Filings3(16%)
  • Earnings1(5%)
  • Leadership1(5%)
  • Offering1(5%)

Latest news

25 items

AXGN FAQ

6 questions
  • What does Axogen Inc. do?
    AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged...
  • Where does AXGN stock trade?
    Axogen Inc. (AXGN) is listed on NASDAQ.
  • What sector and industry is AXGN in?
    Axogen Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.
  • What are analysts saying about AXGN?
    Axogen Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $4000.00 price target on 2026-02-19. Recent price targets range from $1300.00 to $4000.00.
  • What companies are similar to AXGN?
    Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare AXGN side-by-side with any of them on Quantisnow.
  • How can I track AXGN on Quantisnow?
    Quantisnow aggregates Axogen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXGN to receive live email and push alerts on every new disclosure.